143 related articles for article (PubMed ID: 2338628)
1. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
2. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
Lankford SM; Maskasame C; Bai SA
Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
[TBL] [Abstract][Full Text] [Related]
3. The influence of diltiazem versus cimetidine on propranolol metabolism.
Tateishi T; Ohashi K; Fujimura A; Ebihara A
J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
[TBL] [Abstract][Full Text] [Related]
4. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
5. Influence of aging on the oxidative and conjugative metabolism of propranolol.
Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
[TBL] [Abstract][Full Text] [Related]
6. Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration.
Drummer OH; McNeil J; Pritchard E; Louis WJ
J Pharm Sci; 1981 Sep; 70(9):1030-2. PubMed ID: 6101148
[TBL] [Abstract][Full Text] [Related]
7. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
8. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
Walle T; Walle UK; Olanoff LS; Conradi EC
Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
10. Presystemic and systemic glucuronidation of propranolol.
Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of sustained release propranolol formulations.
McAinsh J; Baber NS; Holmes BF; Young J; Ellis SH
Biopharm Drug Dispos; 1981; 2(1):39-48. PubMed ID: 7236870
[TBL] [Abstract][Full Text] [Related]
12. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation.
Ghabrial H; Nand R; Stead CK; Smallwood RA; Morgan DJ
J Pharm Sci; 1994 Jul; 83(7):931-6. PubMed ID: 7965671
[TBL] [Abstract][Full Text] [Related]
13. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation.
Marino MR; Dey M; Garg DC; Jallad NS; Dorick DM; Martinez JJ; Weidler DJ
J Clin Pharmacol; 1987 Nov; 27(11):885-91. PubMed ID: 3429696
[TBL] [Abstract][Full Text] [Related]
15. Propranolol metabolism in normal subjects: association with sex steroid hormones.
Walle T; Walle K; Mathur RS; Palesch YY; Conradi EC
Clin Pharmacol Ther; 1994 Aug; 56(2):127-32. PubMed ID: 8062488
[TBL] [Abstract][Full Text] [Related]
16. Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans.
Sharoky M; Perkal M; Turner R; Lesko LJ
Biopharm Drug Dispos; 1988; 9(5):447-56. PubMed ID: 3224162
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of conventional and controlled release dosage form of propranolol.
Das SK; Chattaraj SC
Arzneimittelforschung; 1990 Jul; 40(7):752-4. PubMed ID: 2222550
[TBL] [Abstract][Full Text] [Related]
18. Quantitative account of propranolol metabolism in urine of normal man.
Walle T; Walle UK; Olanoff LS
Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
20. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
